The sentinel node biopsy concept as applied in breast cancer is producing important changes in the management of patients affected by infiltrating carcinoma. At the European Institute of Oncology, sentinel node biopsy experience started in early 1996, and from March 1996 to April 2001, a total of 2511 patients affected by operable breast cancer underwent lymphoscintigraphy and sentinel node biopsy. In the first phase of our study, we found that administration of large-size (200 nm to 1000 nm) colloid particles afforded better and easier localization of the sentinel node than small-size tracer particles and that subdermal and peritumoral injections were more suitable than intratumoral administration. Lymphoscintigraphy was performed 3 to 20 hours before surgery, with injection of 10 to 15 MBq of technetium Tc 99m-labeled colloid particles of human serum albumin in a volume of 0.2 to 0.5 mL. According to this approach, the sentinel node was easily identified and removed in 98.8 % of cases.
|Number of pages||5|
|Journal||Seminars in Breast Disease|
|Publication status||Published - 2002|
ASJC Scopus subject areas